ProtoKinetix, Incorporated announced its collaboration with IQVIA to accelerate development of AAGP® (PKX-001) in ocular conditions, specifically Dry Eye Disease and Wet and Dry forms of Age-related Macular Degeneration. The ProtoKinetix-IQVIA collaboration will aim to accelerate the clinical development and regulatory progress of PKX-001. The collaboration is expected to drive directed clinical development as PKX-001 enters Phase 1 testing for the above conditions.

This initiative will also serve to optimize these clinical trials to determine safety in these new conditions, drawing from previous experience with PKX-001 in Type 1 diabetes and other conditions.